64例中晚期宫颈癌同步放化疗临床疗效分析

The clinical efficacy and adverse reactions of the concurrent radiochemotherapy in treatment of advanced cervical cancer

目的观察应用同步放化疗治疗中晚期宫颈癌的临床疗效和不良反应。方法以64例Ⅱb~Ⅳ期中晚期宫颈癌同步放化疗患者为观察组;以同期收治的52例行非同步放化疗的Ⅱb~Ⅳ期宫颈癌患者为对照组,比较两组的治疗结果,并分析同步放化疗治疗的疗效及耐受性。结果观察组:完全缓解(CR)51例(79.7%),部分缓解(PR)7例(10.9%),放化疗结束后宫颈刮片阴性61例(95.3%);所有病例治疗后均已满5年,观察组1、2、3、5年生存率分别是87%、79%、60.1%和53%。非同步放化疗组:完全缓解(CR)28例(53.8%),部分缓解(PR)7例(13.5%),放疗结束后宫颈刮片阴性47例(90.4%);1、2、3、5年生存率分别为89.1%、77.9%、46.3%和30.1%。观察组毒副反应略高于对照组,但经一般处理后,所有病人均可耐受。结论中晚期宫颈癌同步放化疗可提高近期疗效,降低远处转移率,提高患者生存率。虽然毒副反应略有增加,但处理得当,仍然具有较好的临床耐受性。

Objective To evaluate the clinical efficacy and adverse reactions of the concurrentradiochemotherapy in the treatment of advanced cervical cancer. Methods 64 cases of advanced cervical cancer in II b^IV phase patients as the observation group were treated with concurrent radiochemotherapy. 52 cases of patients as control group were treated with non-synchronous radiochemotherapy. The efficacy and tolerance of concurrent radiochemotherapy were analyzed. Re- suits In observation group, complete remission （CR） was 51/64（79.7~）, partial remission（PR） was 7/64（10.9~）, Negative cervical smears after radiochemotherapy was 61/64 （95.3~）. 1,2,3 and 5-year survival rate of observation group was 87 %, 79 ~/~o, 60. 10/~ and 53%, respectively. In non-synchronous radiochemotherapy group, complete remission （CR） was 28/52（53.8%） ,partial remission （PR） was 7/52（13.5%） ,negative cervical smears was 47/52 90.4~）. 1,2,3 and 5-year survival rates were 89.1~ ,77.9~ ,46.3% and 30. 1~, respectively. It could be found that the toxicity reac- tion in the observation group was slightly higher than that of the control group. However, all patients can be tolerated af- ter a general treatment. Conclusion Concurrent radiochemotherapy for advanced cervical cancer could improve short-term effect, reduce the rate of distant metastasis and improve survival rate. Although there was a slight increase in toxicity.